The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis

Published: June 28, 2024
Abstract Views: 1368
PDF: 384
Conflict of interest: 237
SUPPLEMENTARY MATERIAL: 225
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to improve health status in patients with heart failure (HF). We aim to evaluate the effect of SGLT2i on health status [by Kansas City Cardiomyopathy Questionnaire (KCCQ)] and if effect varied by ejection fraction (EF). Randomized clinical trials of SGLT2i in patients with HF till November 2022 were assessed. Change in KCCQ total symptom score (TSS), clinical summary score (CSS), and overall summary score (OSS) from baseline to 12-16 weeks, 32 weeks, and 52 weeks follow-up were assessed. Weighted mean differences (MD) in scores and odds ratios (OR) were pooled using a random-effects model. Twelve trials (n=23,679) were included. SGLT2i significantly improved KCCQ-TSS at 12-16 weeks [MD 2.16 (1.67, 2.65); p<0.001], 32 weeks [MD 1.98 (1.43, 2.54); p<0.001] and 52 weeks [MD 1.94 (1.19, 2.69); p<0.001] follow-up. At 12-16 weeks, patients treated with SGLT2i had significantly higher odds of KCCQ-TSS improvement by ≥5 points [OR 1.27 (1.16, 1.39); p<0.001], ≥10 points [OR 1.21 (1.11, 1.32); p<0.001] and ≥15 points [OR 1.23 (1.14, 1.33); p<0.001]. Similar results were observed at mid- and long-term follow-up, and for CSS and OSS. For all analyses, findings were consistent between patients with HF with reduced or preserved EF, acute/worsening or chronic HF, and which SGLT2i used (p-interaction >0.20 for all). SGLT2i improve health status in patients with HF, with consistent and sustained benefits across all summary scores and HF subtypes. Treatment benefits were apparent within months of initiation and sustained to at least 1 year.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol 2020;76:2379-90. DOI: https://doi.org/10.1016/j.jacc.2020.09.542
Anita AK, John S, Peter P, et al. Utility of Patient-reported outcome instruments in heart failure. JACC Heart Failure 2016;4:165-75. DOI: https://doi.org/10.1016/j.jchf.2015.10.015
Food and Drug Administration. Treatment for heart failure: endpoints for drug development guidance for industry. 2019. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatment-heart-failure-endpoints-drug-development-guidance-industry. Accessed on October 2022.
Food and Drug Administration. DDT COA #000084: Kansas City Cardiomyopathy Questionnaire (KCCQ). 2020. Available from: https://www.fda.gov/drugs/clinical-outcome-assessment-coa-qualification-program/ddt-coa-000084-kansas-city-cardiomyopathy-questionnaire-kccq. Accessed on October 2022.
Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 2019;140:1463-76. DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.042929
Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation 2020;141:90-9. DOI: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Butler J, Anker SD, Filippatos G, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-reduced trial. Eur Heart J 2021;42:1203-12. DOI: https://doi.org/10.1093/eurheartj/ehaa1007
Nassif ME, Windsor SL, Borlaug BA, et al. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 2021;27:1954-60. DOI: https://doi.org/10.1038/s41591-021-01536-x
Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-preserved trial. Circulation 2022;145:184-93. DOI: https://doi.org/10.1161/CIRCULATIONAHA.121.057812
Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol 2022;80:1302-10. DOI: https://doi.org/10.1016/j.jacc.2022.07.021
Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med 2022;28:809-13. DOI: https://doi.org/10.1038/s41591-022-01703-8
Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening. Heart Failure 2020;384:117-28. DOI: https://doi.org/10.1056/NEJMoa2030183
Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status in patients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023;81:460-73. DOI: https://doi.org/10.1016/j.jacc.2022.11.006
Muhammad Shariq U, Tariq Jamal S, Stefan DA, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol 2023;81:2377-87. DOI: https://doi.org/10.1016/j.jacc.2023.04.034
Yang D, Zhang Y, Yan J, Liu M, An F. SGLT-2 inhibitors on prognosis and health-related quality of life in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Front Cardiovasc Med 2022;9:942125. DOI: https://doi.org/10.3389/fcvm.2022.942125
Treewaree S, Kulthamrongsri N, Owattanapanich W, Krittayaphong R. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: an updated systematic review and meta-analysis. Front Cardiovasc Med 2023;10. DOI: https://doi.org/10.3389/fcvm.2023.1046194
He Z, Yang L, Nie Y, et al. Effects of SGLT-2 inhibitors on health-related quality of life and exercise capacity in heart failure patients with reduced ejection fraction: a systematic review and meta-analysis. Int J Cardiol 2021;345:83-8. DOI: https://doi.org/10.1016/j.ijcard.2021.10.008
Chambergo-Michilot D, Tauma-Arrué A, Loli-Guevara S. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis. Int J Cardiol Heart Vasc 2021;32:100690. DOI: https://doi.org/10.1016/j.ijcha.2020.100690
Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022;400:757-67. DOI: https://doi.org/10.1016/S0140-6736(22)01429-5
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. DOI: https://doi.org/10.1136/bmj.n71
Spertus JA, Jones PG. Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qual Outcomes 2015;8:469-76. DOI: https://doi.org/10.1161/CIRCOUTCOMES.115.001958
Jensen J, Omar M, Kistorp C, et al. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: a double-blinded, randomized, and placebo-controlled trial. Am Heart J 2020;228:47-56. DOI: https://doi.org/10.1016/j.ahj.2020.07.011
Abraham WT, Lindenfeld J, Ponikowski P, et al. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J 2021;42:700-10. DOI: https://doi.org/10.1093/eurheartj/ehaa943
Kosiborod MN, Angermann CE, Collins SP, et al. Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation 2022;146:279-88. DOI: https://doi.org/10.1161/CIRCULATIONAHA.122.059725
Lewis EF, Claggett BL, McMurray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail 2017;10. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430
Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016;9:e001937. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.114.001937
Peter JV, Katia N, Qinghua L, et al. Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol 2012;60:1940-4. DOI: https://doi.org/10.1016/j.jacc.2012.06.054
Butler J, Khan MS, Mori C, et al. Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. Eur J Heart Fail 2020;22:999-1005. DOI: https://doi.org/10.1002/ejhf.1810
Masoudi FA, Rumsfeld JS, Havranek EP, et al. Age, functional capacity, and health-related quality of life in patients with heart failure. J Card Fail 2004;10:368-73. DOI: https://doi.org/10.1016/j.cardfail.2004.01.009
Khan MS, Butler J. Stability of changes in health status: next step in comprehensively assessing patient-reported outcomes. JAMA 2022;328:923-4. DOI: https://doi.org/10.1001/jama.2022.13551

How to Cite

Usman, M. S., Hamid, A., Qazi, S. U., Kosiborod, M. N., Bhatt, D. L., Khan, M. S., Vaduganathan, M., & Butler, J. (2024). The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis. Global Cardiology, 2(2). https://doi.org/10.4081/cardio.2024.35

Most read articles by the same author(s)